Evidence map›Paper›PMID 30038414›Full record

ArticleNature methods2018

Genetically engineered cerebral organoids model brain tumor formation.

Shan Bian, Marko Repic, Zhenming Guo, Anoop Kavirayani, Thomas Burkard, Joshua A Bagley, Christian Krauditsch, Jürgen A Knoblich

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Nature methods, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 250 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
250citing papers in PubMed, 1 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

250 citing papers in PubMed, 1 synthesis or guideline pooled it, 394 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

190 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Shan BianInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID http://orcid.org/0000-0003-4507-3003
Marko RepicInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.
Zhenming GuoInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID http://orcid.org/0000-0002-6469-414X
Anoop KavirayaniVienna Biocenter Core Facilities (VBCF), Vienna, Austria.
Thomas BurkardInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID http://orcid.org/0000-0002-0884-2929
Joshua A BagleyInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID http://orcid.org/0000-0002-6825-4264
Christian KrauditschInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria.ORCID http://orcid.org/0000-0003-4933-6675
Jürgen A KnoblichInstitute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna, Austria. juergen.knoblich@imba.oeaw.ac.at.ORCID http://orcid.org/0000-0002-6751-3404
Institute of Molecular Biotechnology · ATVienna Biocenter · AT

Funding

Austrian Science Fund FWF Z 153European Research Council 693184European Research Council 695642
6 · The paper itself

Abstract

Brain tumors are among the most lethal and devastating cancers. Their study is limited by genetic heterogeneity and the incompleteness of available laboratory models. Three-dimensional organoid culture models offer innovative possibilities for the modeling of human disease. Here we establish a 3D in vitro model called a neoplastic cerebral organoid (neoCOR), in which we recapitulate brain tumorigenesis by introducing oncogenic mutations in cerebral organoids via transposon- and CRISPR-Cas9-mediated mutagenesis. By screening clinically relevant mutations identified in cancer genome projects, we defined mutation combinations that result in glioblastoma-like and central nervous system primitive neuroectodermal tumor (CNS-PNET)-like neoplasms. We demonstrate that neoCORs are suitable for use in investigations of aspects of tumor biology such as invasiveness, and for evaluation of drug effects in the context of specific DNA aberrations. NeoCORs will provide a valuable complement to the current basic and preclinical models used to study brain tumor biology.

Indexed as

AnimalsBrain NeoplasmsDisease Models, AnimalGenes, mycGenetic EngineeringGlioblastomaHeterograftsHuman Embryonic Stem CellsHumansMaleMiceMice, NudeMutationNeuroectodermal Tumors, PrimitiveOncogenesOrganoids

Identifiers

PMID30038414
PMCPMC6071863
OpenAlexW2883445821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.